See more : CloudMD Software & Services Inc. (DOCRF) Income Statement Analysis – Financial Results
Complete financial analysis of Tyra Biosciences, Inc. (TYRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyra Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kukdong Oil & Chemicals Co.,Ltd (014530.KS) Income Statement Analysis – Financial Results
- Leonteq AG (LNTQF) Income Statement Analysis – Financial Results
- Cloopen Group Holding Limited (RAASY) Income Statement Analysis – Financial Results
- M. K. Proteins Limited (MKPL.BO) Income Statement Analysis – Financial Results
- St. Modwen Properties Limited (1IG.F) Income Statement Analysis – Financial Results
Tyra Biosciences, Inc. (TYRA)
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| Gross Profit | -353.00K | -296.00K | -140.00K | -47.00K | -8.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.52M | 43.01M | 20.64M | 7.20M | 1.79M |
| General & Administrative | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Other Expenses | 0.00 | -50.00K | -19.00K | -23.00K | -8.00K |
| Operating Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Cost & Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Interest Income | 10.85M | 3.65M | 13.00K | 1.00 | 1.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K |
| Depreciation & Amortization | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| EBITDA | -79.59M | -58.63M | -26.15M | -9.25M | -3.11M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -79.95M | -58.93M | -26.29M | -9.30M | -3.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.81M | 3.60M | -6.00K | -39.00K | -943.00K |
| Income Before Tax | -69.13M | -55.33M | -26.29M | -9.34M | -4.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.60M | -153.00K | -22.00K | -7.00K |
| Net Income | -69.13M | -51.72M | -26.14M | -9.31M | -4.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| EPS Diluted | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
| Weighted Avg Shares Out (Dil) | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
TYRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
The Schall Law Firm Is Inquiring Into Tyra Biosciences Inc.'s Potential Securities Fraud And Affected Investors Can Participate
LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
TYRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
Tyra Biosciences Inc. Shareholders Can Reach Out To The Schall Law Firm About An Investigation Into Possible Breaches Of Securities Laws
LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
Investors With Losses In Tyra Biosciences Inc. Are Urged To Join An Inquiry Into Possible Securities Fraud With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
TYRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Stockholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
Tyra Biosciences Inc. Shareholders Encouraged To Participate In Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
The Schall Law Firm Invites TYRA Stakeholders To Be A Part Of A Securities Fraud Investigation Into Tyra Biosciences, Inc.
LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Stockholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to...
Source: https://incomestatements.info
Category: Stock Reports